Skip to main content

Golimumab (Simponi)

Golimumab is a human monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and uveitis.

It is used as an immunosuppressive drug and targets and inhibits TNF-alpha.

It is administered through intravenous infusion every 8 weeks or subcutaneously every month.

In 2016, it sold €120 million in Europe.

It has an immunogenicity rate of 2-15%.

Labs that test for drug level:

Wieslab
KU Leuven
Sanquin
United Medix Labs

Labs that test for ADA titre:

Wieslab
KU Leuven
Sanquin
United Medix Labs